Clinical Trial Update: Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating the addition of selinexor to temozolomide for recurrent glioblastoma, including MGMT-methylated and IDH-wildtype subtyp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Selinexor (selinexor)
• Temodar (Temozolomide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: MGMT-Methylated Glioblastoma, Recurrent Glioblastoma, IDH-Wildtype | Phase 1, Phase 2 | Status: SUSPENDED